Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isovalerylspiramycin I
- Development stage
- Preclinical
- Lead developer
- Shen Yang Fuyang Medicine Technology
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Isovalerylspiramycin I is a semi-synthetic macrolide antibiotic and a principal active component of carrimycin, derived by acylating the 4'-OH group of spiramycin with an isovaleryl side chain. It features a 16-membered lactone ring structure and exhibits both antibacterial and anticancer properties. Mechanistically, it acts as an inhibitor of topoisomerase 1 (TOP1), directly binding to this enzyme, thereby inhibiting DNA replication in cancer cells. Additionally, it suppresses the ATR/CHEK1 DNA damage repair pathway, leading to increased DNA damage and apoptosis in tumor cells. Isovalerylspiramycin I has demonstrated efficacy against various solid tumors (including osteosarcoma) and shows potential antiviral activity against enterovirus, herpes virus, influenza virus, and HIV[2][3][5][10].
- Other names
- ISP-I
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on isovalerylspiramycin I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isovalerylspiramycin I.